- Home
- DRUG vs DSM Comparison
DRUG vs DSM Comparison
Compare DRUG & DSM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DRUG
- DSM
- Stock Information
- Founded
- DRUG 2019
- DSM 1989
- Country
- DRUG United States
- DSM United States
- Employees
- DRUG N/A
- DSM N/A
- Industry
- DRUG Pharmaceuticals and Biotechnology
- DSM Investment Managers
- Sector
- DRUG Health Care
- DSM Finance
- Exchange
- DRUG Nasdaq
- DSM Nasdaq
- Market Cap
- DRUG 233.2M
- DSM 270.9M
- IPO Year
- DRUG N/A
- DSM N/A
- Fundamental
- Price
- DRUG $27.31
- DSM $5.59
- Analyst Decision
- DRUG Strong Buy
- DSM
- Analyst Count
- DRUG 6
- DSM 0
- Target Price
- DRUG $83.25
- DSM N/A
- AVG Volume (30 Days)
- DRUG 19.6K
- DSM 161.7K
- Earning Date
- DRUG 08-13-2025
- DSM 01-01-0001
- Dividend Yield
- DRUG N/A
- DSM 3.97%
- EPS Growth
- DRUG N/A
- DSM N/A
- EPS
- DRUG N/A
- DSM N/A
- Revenue
- DRUG N/A
- DSM N/A
- Revenue This Year
- DRUG N/A
- DSM N/A
- Revenue Next Year
- DRUG N/A
- DSM N/A
- P/E Ratio
- DRUG N/A
- DSM N/A
- Revenue Growth
- DRUG N/A
- DSM N/A
- 52 Week Low
- DRUG $0.93
- DSM $4.69
- 52 Week High
- DRUG $79.02
- DSM $6.05
- Technical
- Relative Strength Index (RSI)
- DRUG 41.95
- DSM 48.92
- Support Level
- DRUG $27.69
- DSM $5.53
- Resistance Level
- DRUG $28.74
- DSM $5.64
- Average True Range (ATR)
- DRUG 1.29
- DSM 0.04
- MACD
- DRUG 0.14
- DSM 0.00
- Stochastic Oscillator
- DRUG 39.29
- DSM 64.29
About DRUG Bright Minds Biosciences Inc.
Bright Minds Biosciences Inc is focused on developing novel transformative treatments for neuropsychiatric disorders, epilepsy, and pain. The company has a portfolio of next-generation serotonin agonists designed to target neurocircuit abnormalities that are responsible for difficult to treat disorders such as resistant epilepsy, treatment resistant depression, PTSD, and pain. The company's drugs have been designed to potentially retain the powerful therapeutic aspects of psychedelic and other serotonergic compounds, while minimizing the side effects, thereby creating superior drugs to first-generation compounds, such as psilocybin.
About DSM BNY Mellon Strategic Municipal Bond Fund Inc.
BNY Mellon Strategic Municipal Bond Fund, Inc. is a diversified closed-end management investment company. Its investment objective is to seek to maximize current income exempt from federal income tax to the extent consistent with the preservation of capital.